NasdaqCM:MLTXBiotechs
How Psoriatic Arthritis Trial Success and Q2 Losses Could Shape MoonLake Immunotherapeutics (MLTX) Investors
MoonLake Immunotherapeutics reported second-quarter 2026 results, posting a net loss of US$61.81 million (US$0.84 basic loss per share) and announcing that its Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve adults with active psoriatic arthritis met all clinical endpoints at Week 16.
The trial’s topline data showed clinically meaningful improvements across joint, skin and quality-of-life measures, reinforcing sonelokimab’s potential to address multiple manifestations of psoriatic...